Skip to main content

Table 1 Distribution of the PIN3 16-bp duplication polymorphism of TP53 according to the clinicopathological characteristics in Malian breast cancer

From: Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis

Clinical parameter

N (%)

PIN3 16-bp duplication

X2

P value

A1A1%

A1A2%

A2A2%

Mean age at diagnosis

43.72 ± 3.14

2.41*

0.12

  ≤ 40 years of age

29 (48.3)

11 (37.9)

12 (41.4)

6 (20.7)

  

  > 40 years of age

31 (51.7)

16 (51.6)

13 (41.4)

2 (6.5)

  

Localization

    

1.98

0.74

 Right breast

19 (31.7)

7 (36.8)

9 (47.4)

3 (15.8)

  

 Left breast

37 (61.7)

19 (51.4)

14 (37.8)

4 (10.8)

  

 Bilateral

4 (6.6)

1 (25.0)

2 (50.0)

1 (25.0)

  

Use of contraceptives

   

0.56*

0.45

 No

45 (75.0)

18 (40.0)

25 (55,6)

2 (4.4)

  

 Yes

15 (25.0)

9 (60.0)

6 (40.0)

  

Menopausal status

    

3.15

0.53

 Pre-menopausal

11 (18.3)

6 (54.5)

4 (36.4)

1 (9.1)

  

 Post-menopausal

20 (33.3)

10 (50.0)

9 (45.0)

1 (5.0)

  

 Fertile women

29 (48.3)

11 (37.9)

12 (41.4)

6 (20.7)

  

Parity

    

7.33

0.12

 Nulliparity

6 (10.0)

5 (83.3)

1 (16.7)

  

 Primiparity

9 (15.0)

3 (33.3)

4 (44.4)

2 (22.2)

  

 Multiparity

45 (75.5)

24 (53.3)

16 (35.6)

5 (11.1)

  

Breastfeeding

    

0.50*

0.48

 Yes

53 (88.3)

26 (49.1)

19 (35.8)

8 (15.1)

  

 No

7 (11.7)

1 (14.3)

6 (85.7)

  

Family history of BC

    

0.64*

0.42

 Yes

8 (13.3)

4 (50.0)

4 (50.0)

  

 No

52 (86.7)

23 (44.2)

21 (40.4)

8 (15.4)

  

Personal history of benign breast disease

    

1.69*

0.19

 Yes

6 (10.0)

4 (66.7)

2 (33.3)

  

 No

54 (90.0)

23 (42.6)

23 (42.6)

8 (14.8)

  

Obesity

    

0.43

0.81

 Yes

19 (31.7)

8 (42.1)

9 (47.4)

2 (10.5)

  

 No

41 (68.3)

19 (46.3)

16 (39.0)

6 (14.6)

  

Smoking

    

0.20*

0.65

 Passive smoking

7 (11.7)

3 (42.9)

4 (57.1)

  

 No

53 (88.3)

24 (45.3)

21 (39.6)

8 (15.1)

  

Histological type

    

4.14*

0.04

 Invasive ductal carcinoma

56 (93.3)

23 (41.1)

25 (44.6)

8 (14.3)

  

 Others

4 (6.7)

4 (100.0)

  

Tumor size

    

5.63

0.46

 T1

1 (1.7)

1 (100.0)

  

 T2

10 (16.7)

5 (50.0)

5 (50.0)

  

 T3

41 (68.3)

18 (43.9)

15 (36.6)

8 (19.5)

  

 T4

8 (13.3)

4 (50.0)

4 (50.0)

  

Nodal involvement

      

 N0

36 (60.0)

16 (44.4)

16 (44.4)

4 (11.1)

6.05

0.41

 N1

16 (26.7)

5 (31.3)

7 (43.8)

4 (25.0)

  

 N2

7 (11.7)

5 (71.4)

2 (28.6)

  

 N3

1 (1.7)

1 (100.0)

  

Metastasis

    

0.91*

0.34

 M0

55 (91.7)

24 (43.6)

23 (41.8)

8 (14.5)

  

 M1

5 (8.3)

3 (60.0)

2 (40.0)

  
  1. X2 Chi-squared test, P p-value, * Chi-squared test two-sided, N Number, BC Breast cancer, A1A1 Wild-type, A1A2 heterozygous, A2A2 homozygous mutant, % Percentagwe, Other histological type: Glycogen-rich clear cell carcinoma, lobular carcinoma in situ, Moderately differentiated adenocarcinoma and infiltrating adenocarcinoma.